Global Chronic Kidney Disease Drugs Market 2019-2025: Increasing CKD Incidence, Ageing Population, Promising Repayments & Reimbursement Plans – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic
Kidney Disease Drugs Market – Global Forecast to 2025” report
has been added to ResearchAndMarkets.com’s offering.

The report predicts that the Global Chronic Kidney Disease Drugs Market
will grow at a CAGR of 4.1% during the forecast period

The market has witnessed flat growth in the past few years and is
sustaining only due to the steady rise in the incidence of renal
disorders leading to chronic kidney disease, increasing incidences of
cardiovascular and metabolism-related disorders, and growing geriatric
population globally.

The growing market trend continues and is one of the increasingly
accepted markets in many countries worldwide. Chronic kidney disease
drugs manufacturers are focusing on obtaining funds and collaborating
with universities to enlarge their R&D capabilities. A majority of the
revenue is generated from the leading players in the market with
dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and
AstraZeneca.

According to the author’s analysis, North America accounted for the
largest share of the global chronic kidney disease drugs market in 2018.
The US dominates the market owing to the presence of a majority of the
chronic kidney disease drugs manufacturers in the region. However, the
fastest growth rate is anticipated to be in the APAC region due to the
large kidney disease patient population and increasing awareness about
the disease.

The antihypertensives segment occupied the largest share in 2018.
Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2
randomized clinical trial on KBP-5074 for patients with
moderate-to-severe chronic kidney disease and uncontrolled hypertension.

In 2018, hospitals accounted for the maximum share, followed by
speciality clinics, due to the availability of technologically-advanced
diagnostic equipment for the early diagnosis of the condition.

North America is dominant in the global chronic kidney disease drugs
market, followed by Asia Pacific and Europe. The significant share of
the North America market comes from the US due to the availability of
good reimbursement policies.

Various initiatives are taken by government establishments and market
players to increase awareness among individuals. Campaigns are conducted
globally to encourage people in adopting healthy lifestyles. Many
countries are focusing on national programs to create disease awareness,
prevention, and treatment options; for example, country-level national
dialysis program, kidney disease education portals, the launch of
kidney-related disorder treatment funding initiatives, etc. Exhaustive
pipeline for chronic kidney disease drugs is promising and is much
required for future market growth.

For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied
in Phase-III clinical trials in the US, Europe, China, and Japan.
Dapagliflozin by AstraZeneca is currently in phase III to evaluate the
effect of dapagliflozin on renal outcomes and cardiovascular mortality
in patients with chronic kidney disease (Dapa-CKD).

Key Competitive Facts

• Increasing CKD incidence, ageing population, promising repayment or
  reimbursement plans in few nations, and enormous R&D activities for
  the CKD drug development are the major factors driving the market
  growth.
• Cell therapy produces better results in the earlier stages of kidney
  disease and has been shown to eliminate or reduce the need for regular
  dialysis.
• Research is being conducted to study the potential of miRNA as
  effective biomarkers and therapeutic targets for CKD treatments.

Key Topics Covered:

1 Industry Outlook

2 Report Outline

3 Market Snapshot

3.1 Market Definition

3.2 Segmented Addressable Market (SAM)

3.3 Industry Trends

3.4 Related Markets

3.4.1 Active pharmaceutical ingredients (APIs)

3.4.2 Over-the-counter drugs (OTC)

3.4.3 Human Insulin

4 Market Outlook

4.1 Market Segmentation

4.2 Porter 5 (Five) Forces

5 Market Characteristics

5.1 Market Dynamics

5.1.1 Drivers

5.1.1.1 High incidence of chronic kidney disease (CKD)

5.1.1.2 Rise in incidence of cardiovascular disorders and diabetes

5.1.1.3 Increase in global geriatric population

5.1.2 Restraints

5.1.2.1 Competition from biosimilars

5.1.2.2 Complex drug development process

5.1.3 Opportunities

5.1.3.1 Promising Drug Pipeline Chronic Kidney Disease

5.1.3.2 Market expansion opportunities in emerging nations

5.1.3.3 Novel therapeutic approaches such as cell therapy

5.1.4 DRO – Impact Analysis

5.2 Key Stakeholders

6 Drug Class: Market Size and Analysis

6.1 Overview

6.2 Anti-hypertensives

6.1 Anti-hyperlipidemic

6.2 Erythropoiesis-stimulating agents (ESAs)

6.3 Diuretics Drugs

6.4 Others

7 End Users: Market Size and Analysis

7.1 Overview

7.2 Hospitals

7.3 Specialty Clinic

8 Regions: Market Size and Analysis

9 Competitive Landscape

10 Vendors Profile

10.1 AbbVie Inc.

10.1.1 Overview

10.1.2 Geographic Presence

10.1.3 Business Focus

10.1.4 SWOT Analysis

10.1.5 Business Strategies

10.2 Amgen Inc.

10.3 GlaxoSmithKline plc

10.4 F. Hoffmann-La Roche Ltd.

10.5 Astra Zeneca PLC

11 Companies to Watch for

11.1 Pfizer Inc.

11.2 Sanofi

11.3 Teva Pharmaceutical Industries Ltd.

11.4 Johnson & Johnson

11.5 Keryx Biopharmaceuticals Inc

11.6 FibroGen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/pahun1

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs